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Genome organization inside the nucleus is hierarchically organized1. Chromosomes are organized into chromosome territories2. Inside chromosome territories, certain regions 
of the chromatin are attached to the nuclear periphery and form 
repressive nuclear lamin-associated domains (LADs)3. Recent chro-
mosome conformation studies have revealed that mammalian chro-
mosomes are structured into largely tissue-invariant TADs in which 
the DNA interactions are more frequent within a given domain than 
with regions in other domains4,5. TADs are considered to represent 
functional domains because a given TAD encompasses the regula-
tory elements for the genes inside the same domain6,7. Therefore, 
the integrity of the domain structures is important for the proper 
regulation of genes8–12. The disruption of domain boundaries can 
result in ectopic interactions between neighboring domains and 
affect the regulation of nearby genes5,9. Regulatory landscapes are an 
important part of human malignancies, and studies have shown that 
the ‘hijacking’ of enhancers can lead to overexpression of oncogenes 
(for example, growth factor independent 1 family oncogenes (GFI1 
and GFI1B)) in medulloblastoma13 or proto-oncogene MECOM 
activation due to an inversion between TADs in acute myeloid leu-
kemia cells, which facilitates tumor formation14. Several other stud-
ies have reported the deregulation of chromatin folding structures 
in different cancer types11,15,16. Hence, genomic rearrangements can 
have a significant role in the reshuffling of TAD structures that 
results in altered gene regulation. Despite these recent examples of 
SVs that result in altered local enhancer–promoter landscapes, the 
frequency of such regulatory architecture rearrangements in cancer 
genomes remains unclear. Similarly, whether there are loci affected 
by potential changes in regulatory structure outside of those 
currently reported in the literature is unknown. To address these 
questions, we comprehensively characterized the effects of differ-
ent SVs on TADs and gene-expression patterns observed in various 
tumor types to expand understanding of the link between chroma-
tin folding and genomic rearrangements in cancer genomes.
Results
TAD boundaries are affected by different types of somatic SV in 
cancer genomes. Previous reports have indicated that TADs are a 
largely cell-type-invariant feature of genome organization4,17. In this 
pan-cancer analysis, we sought to generate a common set of bound-
aries observed in different cell types. We used high-resolution chro-
mosome conformation (Hi-C) datasets from five human cell lines 
that represent three distinct embryonic germ layers (GM12878 and 
HMEC, mesoderm; IMR90, endoderm; HUVEC and NHEK, ecto-
derm)17 to identify TAD boundaries in different cell types (Extended 
Data Fig. 1a). We called TAD boundaries from 25-kb-binned Hi-C 
data for each cell type with an insulation score18 approach. This 
method calculates a score (TAD signal), for each bin, for the aver-
age interactions with the nearby loci for a 2-Mb genomic window. 
Boundaries are determined as regions with local insulation minima 
along the diagonal of the Hi-C matrix18. As a result, a number of 
boundaries, which ranged from 3,926 to 4,690, were found for dif-
ferent cell types. We next investigated whether our TAD boundary 
calls were consistent with the previously reported boundaries and 
showed attributes of TAD boundaries. To test this, we compared 
available boundary regions for IMR90 cells that were identified 
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using a directionality-based approach (with a bin size of 40 kb)4. 
Our IMR90 boundary calls were highly overlapping (>84%) with 
published boundaries (Extended Data Fig. 1b). This showed that the 
current boundary regions were comparable with previously mapped 
boundaries even though they were identified at a different Hi-C res-
olution and using a different detection algorithm. Furthermore, we 
observed known TAD boundary signatures4 around our boundary 
calls for each cell type (Extended Data Fig. 1c). Across all cell types, 
we identified a common set of 2,477 boundaries (Supplementary 
Table 1, Extended Data Fig. 1d). There was a significant (P < 10−6) 
overlap (a 50-kb distance was allowed) between TAD boundaries 
among all profiled cell types. The median distance between the 
common boundaries was approximately 750 kb, consistent with the 
reported median TAD size in human cells4,19 (Extended Data Fig. 1e). 
The resulting 2,477 common regions were used for the rest of the 
analyses (referred to as boundaries hereafter).
Next, to test whether the overall chromatin architecture is similar 
in cancer and non-cancer cells, we intersected these boundaries with 
the TAD boundaries found in cancer cell lines. We observed a high 
overlap with boundaries from a leukemia cell line K562 (ref. 17) and 
a breast cancer cell line MCF7 (ref. 20) (85% and 83.4%, respectively; 
Extended Data Fig. 1f,g). These analyses revealed that a significant 
(P < 10−7) percentage of boundaries was conserved between normal 
and malignant cells. We next examined the enrichment of CCCTC-
binding factor (CTCF)-binding and DNase I hypersensitivity sites, 
as well as active transcription start sites and heterochromatic regions 
around boundaries from various cell types that have previously 
been profiled by the Encyclopedia of DNA Elements (ENCODE) 
consortium19 and the Roadmap Epigenome project21. We observed 
that CTCF-binding sites and active promoter marks were enriched, 
whereas the heterochromatin state was depleted at the boundaries. In 
addition, TAD signal levels were the lowest at the boundaries com-
pared with flanking sites (Fig. 1a), consistent with the role of TAD 
boundaries in the reduction of the contacts between adjacent domains. 
Overall, these common 2,477 boundaries exhibited the genomic fea-
tures of TAD boundaries across different human cell types.
To understand the effects of SVs on TAD boundaries in human 
cancers, we used 288,457 high-confidence somatic SVs as part of 
the ICGC PCAWG project. The PCAWG Consortium aggregated 
whole-genome sequencing (WGS) data from 2,658 cancers across 
38 tumor types generated by the ICGC and TCGA projects. These 
sequencing data were re-analyzed with standardized, high-accuracy 
pipelines to align to the human genome (reference build hs37d5) 
and identify germline variants and somatically acquired mutations, 
as described in the lead paper of the PCAWG Consortium22. We used 
SV breakpoint orientations as a measurement to classify deletions, 
inversions, duplications or complex rearrangements as described 
previously23. Complex rearrangements included chromothripsis24 
and other alterations, which covered SV break-ends with concomi-
tant deletions, inversions or duplications. SVs were further catego-
rized into two subgroups based on the length of the events—SVs 
that were longer than 2 Mb in genomic length (long-range SVs) and 
shorter than 2 Mb in genomic length (short-range SVs). The major-
ity of deletions, inversions and duplications could be categorized 
as short-range; however, complex events tended to be longer in 
length (Extended Data Fig. 2a). In this study, we focused on short-
range SVs because long-range SVs could affect multiple boundar-
ies due to the genomic length of the event. We identified SVs that 
affected the TAD boundaries (boundary affecting (BA)) as the ones 
that spanned the whole length of a boundary (around 75 kb). As 
a result, 5.0%, 8.5%, 12.8% and 19.9% of all deletions, inversions, 
duplications and complex events were called BA events, respectively 
(Fig. 1b). Compared with the expected number of boundary disrup-
tions based on randomly shuffled boundaries, these ratios are strongly 
enriched in BA-duplications (P < 10−4, 1.43-fold enrichment). 
In contrast, we observed a depletion (0.87-fold enrichment, 
P = 0.052) in BA-deletions, whereas BA-inversions and BA-complex 
events occurred at expected levels (P > 0.05) compared with the 
shuffled TAD boundaries (Fig. 1c). Overall, these results suggest 
that deletions tended to occur within the same TAD, whereas dupli-
cations tended to span regions across different TADs.
In cancer cells, boundaries are affected to various degrees due 
to structural alterations, which suggests that some mechanistic dif-
ferences could cause different SV types. Length distributions of the 
BA-SVs were uniformly distributed (Extended Data Fig. 2b). Most 
of the BA-SVs targeted a single boundary; 74% of BA-deletions, 65% 
of BA-inversions, 71% of BA-duplications and 64% of BA-complex 
events affected a single boundary per variant (Fig. 1d). The number 
of affected boundaries did not markedly change with the minimum 
length of the SVs (Fig. 1d, Extended Data Fig. 2c). The majority 
(98.4%) of the boundaries were affected in cancer genomes, although 
a few boundaries were located in the low-mappability regions of 
the genome. Interestingly, TAD boundaries are significantly less 
likely (P < 0.02) to be affected by known deletion and duplication 
polymorphisms derived from genomes of healthy human popula-
tions25–27 (Extended Data Fig. 2d). Genomic length of the germline 
alterations tends to be shorter compared with somatic alterations 
observed in tumors due to negative selection against large SVs in the 
germline28. Therefore, we selected germline and somatic deletions 
with a genomic length between 75 kb and 250 kb that occurred in 
all cancer samples (Fig. 1e). This filtering ensured that the selected 
somatic (median, 137 kb) or germline (median, 113 kb) deletions 
had the length potential to disrupt TAD boundaries. We observed 
that germline deletions that affected TAD boundaries were rare 
(less than 0.1%; 6 affected out of total 924 deletions) compared with 
somatic deletions (4.1%), even in cases in which similar genomic 
ranges and less than 1% of the total boundaries were affected by 
germline events, suggesting that germline variations in TAD bound-
aries may not be as well tolerated as similar somatic alterations.
Chromatin folding disruptions are specific to histological sub-
types. We next focused on the distributions of BA-SVs across 38 
different histological cancer subtypes22. The number of BA-SVs gen-
erally followed the total number of SVs in a given cancer type. Our 
analysis revealed that, among all cancer types, leiomyosarcoma and 
uterus adenocarcinoma had higher numbers with—on average—25 
and 22 BA-SVs per sample, respectively, compared with a median 
of around 7 BA-SVs per sample across all cancer samples (Fig. 2a, 
b). Ovarian, esophageal and breast adenocarcinomas also contained 
high numbers of BA-SVs with—on average—20, 19 and 18 BA-SVs 
per sample, respectively. On the other hand, hematopoietic cancers 
(myeloid-MDS or myeloid-AML) had the lowest BA-SV rates. Only 
glioblastoma samples (CNS-GBM) showed lower-than-expected 
BA-SVs (P < 10−3) across all cancer types. The median SV length of 
a given cancer type was not strongly correlated with the observed 
distributions (r2 = 0.03–0.45) (Extended Data Fig. 3a). The observed 
differences in BA-SV rates are likely driven by the differences in 
the burden and mechanisms of SVs across histological types. For 
instance, leiomyosarcoma and esophageal adenocarcinoma had a 
higher complex SV burden and, as a result, observed BA events were 
also mostly complex rearrangements (Fig. 2b), whereas ovary and 
stomach adenocarcinoma samples contained BA-duplications due 
to an overall higher duplication rate (Fig. 2b). Similarly, the total 
number of SVs in an individual tumor affects the observed BA-SVs 
in that sample (Fig. 2b, Extended Data Fig. 3b). Long-range BA-SVs 
had similar distributions across histological types. Again, leiomyo-
sarcoma and breast adenocarcinoma contained a higher number 
of BA-SVs compared with other cancer types, whereas leukemia 
samples had no BA-SVs per sample (Extended Data Fig. 4a). Taken 
together, our findings show that the impact of BA-SVs is varied 
substantially across tumor types and these events were reflective of 
overall SV burden and type.
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Recurrently affected boundaries in specific cancer types. Next, 
we sought to identify the affected boundaries near known driver 
genes in the COSMIC cancer gene census29. We noted that many 
of the boundaries of cancer driver genes were altered in specific 
histological subtypes (Fig. 3a, Supplementary Table 2). Of those 
recurrently affected boundaries, two adjacent boundaries between 
KIAA1549 and BRAF were prone to BA-duplications specifically 
in samples of pilocytic astrocytoma (Fig. 3b). This region has pre-
viously been implicated in pilocytic astrocytoma, producing an 
oncogenic fusion between the aforementioned genes30. In addition, 
boundaries near the MDM2 locus were most affected in leiomyo-
sarcoma (Fig. 3b), likely due to neochromosome formations that 
included the MDM2 and CDK4 genes31. We also observed a higher 
mutational load specifically on chromosome 12 in leiomyosarcoma 
samples (Fig. 3b). Another recurrent BA-SV event was the high 
number of BA-deletions around RBFOX1 in colorectal adenocar-
cinoma samples (Extended Data Fig. 4b). We surveyed the BA-SV 
distributions on individual chromosomes and observed a positive 
correlation with the number of boundaries (r2 = 0.68–0.92) and 
gene density (r2 = 0.7–0.85) on a given chromosome (Extended 
Data Fig. 4c,d). Notably, distributions of BA-SVs per chromosome 
were generally specific to the histology subtype; for example, chro-
mosome 17 was affected predominantly by BA-complex events in 
breast and esophageal adenocarcinoma samples (Extended Data 
Fig. 5a,b). These findings emphasize the cancer specificity of 
BA-SVs, in which active mechanisms lead to the overall SV burden 
and type in different tumor types yield potential changes in TAD 
structures, especially around cancer driver genes. We next exam-
ined SVs that occurred within TADs, which potentially resulted in 
the disruption of CTCF–CTCF chromatin loops32. We identified a 
number of chromatin loops that were potentially disrupted in vari-
ous cancer types (Supplementary Table 3). For instance, a CTCF site 
near FOXC1 overlaps with recurrent deletions in esophageal, gas-
tric and colon adenocarcinomas (Fig. 3c). Other potentially altered 
loops include a CTCF site near BCL6 in hepatocellular carcinoma 
and breast adenocarcinoma, and CLCN4 in colorectal adenocar-
cinomas (Extended Data Fig. 6a,b). Therefore, chromatin folding 
perturbations can occur at various scales, include TADs and CTCF–
CTCF chromatin loops in cancer genomes and recurrently altered 
boundaries are generally cancer-type specific.
Most domain disruptions do not result in marked gene-expres-
sion changes. To ascribe potential functional effects of BA-SVs on 
chromatin domains, we annotated the TADs by profiling the context 
of aggregate chromatin states within each TAD. We used a proba-
bilistic approach that calculated the occurrence of chromatin states 
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Fig. 3 | Recurrently affected boundaries in specific cancer types. a, recurrently affected boundaries near known cancer driver genes (y axis) per 
histological type (x axis). The size of the circles indicates the portion of samples harboring a BA-SV event in a specific histological type. The color of 
the circles demonstrates the most common SV type (red, deletion; orange, complex; green, duplication; gray, different SV types were observed) in 
each histological type. b, Top, recurrently duplicated TAD boundaries in pilocytic astrocytoma. Columns of the heat map are TAD boundaries and rows 
represent each pilocytic astrocytoma sample. TAD boundaries affected by BA-duplications are colored in green. The schematic at the bottom shows 
the duplicated boundaries (green boxes) between KIAA1549 and BRAF. Bottom, distribution of BA-complex rearrangement (orange) events across 
chromosomes in each leiomyosarcoma sample. Heat maps show affected TAD boundaries in each leiomyosarcoma sample. The line plot at the bottom 
shows normalized mutation count. c, A potentially affected CTCF–CTCF chromatin loop in esophageal, gastric and colon adenocarcinoma near FOXC1. 
Black boxes show TAD boundaries, arcs represent common CTCF–CTCF loops observed in three different cell types (gray). The signal from CTCF 
chromatin immunoprecipitation followed by sequencing (ChIP–seq) (from the NHEK cell line) analysis is represented by a purple histogram. red vertical 
bars indicate deletions in individual samples of esophageal, gastric and colon adenocarcinoma.
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in cell types recorded in the Roadmap Epigenome data. Coverage of 
15 chromatin state enrichments in each domain was calculated and 
normalized to the length of the domain. The obtained matrix was 
grouped using the k-means clustering approach and five distinct 
groups of TADs were identified similar to a previous classification of 
chromatin domains17,19,33. These groups comprised heterochroma-
tin (61), low/quiescent (705), repressed (481), low-active (764) and 
active (365) domains (Fig. 4a, Supplementary Table 4). In addition, 
we used constitutive LADs34 identified in three different human 
cell types to profile the outcomes of the SVs that occurred between 
LADs and inter-LADs. We evaluated the annotation results by pro-
filing the distributions of domain sizes. Repressed domains were 
larger in size and covered the majority of the genome compared with 
active domains, in agreement with previous TAD annotations19,35 
(Extended Data Fig. 7a,b). The median expression of genes within 
each domain was calculated for 2,921 cancer-free samples from 45 
different tissues (GTEx consortium)36 as well as for samples from 
998 patients with cancer from ICGC expression datasets. Analysis of 
expression levels confirmed that genes within repressed domains or 
LADs had significantly lower expression patterns than genes within 
active domains or inter-LADs (P < 2.2 × 10−16) (Fig. 4b, Extended 
Data Fig. 7c). Furthermore, distributions of replication timing for 
various cell types and open/closed chromatin compartment calls 
from TCGA data37 corroborated the data of the annotated domains 
(Extended Data Fig. 7d,e). Utilizing our domain annotations, we 
checked the distributions of flanking domains for BA-deletion, 
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BA-inversion, BA-duplication or BA-complex events. The major-
ity of the BA-SVs affected the same flanking domain types, such 
as boundaries that separated low and low domains or low-active 
and low-active domains (Extended Data Fig. 8a). However, BA-SVs 
between different domain types occurred significantly more fre-
quently than the expected rate, which suggests that BA-SVs have a 
potential role in gene-expression changes (Extended Data Fig. 8a). 
Therefore, we compared expression values of the genes that reside 
on each side of the SVs.
We initially focused on BA-deletions between repressed and 
active domains, as previous studies showed that fused repressed–
active domains could lead to an upregulation of nearby genes38,39. 
Indeed, genes located on the repressed side of deletions were signifi-
cantly upregulated (P < 0.001, Supplementary Table 5) in samples 
with deletions compared with the rest of the samples in the same his-
tological subtype (Fig. 4c), whereas the same effect was not observed 
for BA-deletions between repressed–repressed or active–active 
domains (Extended Data Fig. 8b). For example, a BA-deletion in a 
malignant lymphoma sample was associated with a 37-fold increase 
in the expression level of WNT4 compared with the rest of samples 
from patients with lymphoma (Fig. 4d). Similarly, a BA-deletion in 
the genome of a patient with breast adenocarcinoma correlated with 
26-fold overexpression of SLC22A2 compared with the rest of the 
patients with breast cancer (Fig. 4e). However, this correlation of gene 
expression with BA-deletions between active and repressed domains 
was not universal. The fold change in expression of SLC2A10 was 
1.10 in a uterus adenocarcinoma sample with a BA-deletion com-
pared with the rest of uterus tumor samples (Fig. 4f). Therefore, 
not every BA-deletion correlated with a marked change in gene 
expression; in fact, only 25% of BA-deletions between repressed 
and active domains coincided with twofold changes in gene expres-
sion (Supplementary Table 5). To use a higher number of events, 
we next extended our analysis to all BA-deletions that occurred 
between different domain types. We classified domains as ‘more’ or 
‘less’ transcriptionally active based on the annotations of domains 
(the ordering of domain types is described in Fig. 4a). This analysis 
resulted in a non-significant (P > 0.05) difference between genes that 
were located on more or less transcriptionally active domains after 
BA-deletions (Fig. 4g); and 14% of all BA-deletions coincided with 
a twofold change (Supplementary Table 5). We observed a similar 
non-significant difference for BA-duplications and BA-complex 
events (Extended Data Fig. 8c, Supplementary Tables 6, 7).
Next, we compared the events between LADs and inter-LADs to 
profile whether alterations in the lamin organization could contrib-
ute to gene expression in tumor samples. We observed that deletions 
significantly occurred in LADs and duplications in inter-LADs, 
whereas SVs were less likely to occur between LADs and inter-LADs 
(Extended Data Fig. 8d). We noticed certain correlations between 
gene expression and events between LADs and inter-LADs—for 
example, a complex rearrangement in a melanoma sample coin-
cided with a sevenfold upregulation of TRIM42 (which resides 
in a LAD) compared with the rest of the patients with melanoma 
(Fig. 4h). Overall, however, we did not observe a significant change 
for deletion, duplication and complex events between LADs and 
inter-LADs (Extended Data Fig. 8e, Supplementary Tables 8–10). 
These observations suggest that gene regulation in cancer genomes 
is multifactorial, although disruptions in chromatin folding domains 
may contribute to expression levels in certain cases, the effects of 
disruption do not always coincide with the expression changes.
Cell-type-specific alterations in chromatin folding patterns by 
different SV types. Next, to evaluate whether BA-SVs indeed altered 
chromatin folding patterns, we generated high-resolution Hi-C 
data for four cancer cell lines (SW480 and SNU-C1 for colorectal 
adenocarcinoma, HCC1954 for breast adenocarcinoma and OE33 
for esophageal adenocarcinoma), which were previously profiled by 
WGS. For the majority of the BA-SVs detected by the WGS data 
(>90%), we were able to observe a change in the folding pattern 
in Hi-C contact maps of the respective cell line (Extended Data 
Fig. 9a). Break-ends of BA-SVs exhibited a strong contact frequency 
(14.6-fold) in cancer cells compared with non-cancerous cells 
(Extended Data Fig. 9b). The shortest BA-event with a detectable 
change in our Hi-C maps was a 460-kb long duplication in SW480 
cells (Extended Data Fig. 9c). By contrast, we observed several dis-
crepancies between SVs detected in WGS data and Hi-C maps. 
These SV break-ends tended to be located in repetitive regions of 
the genome or overlapped with inter-chromosomal translocations 
(Extended Data Fig. 9a,c). Our results demonstrate that BA-SVs 
detected using WGS data generally result in altered chromatin fold-
ing patterns in cancer cells.
We subsequently studied how BA-deletions, BA-inversions, 
BA-duplications and BA-complex rearrangements change the 
contact maps and noticed distinct interaction patterns in chro-
matin contact maps for different BA-SVs (Fig. 5a, Extended Data 
Fig. 9d–f). This observation of specific changes in Hi-C maps due to 
different SV types is consistent with findings from a recent study40. 
Furthermore, it has also been suggested that SVs could lead to TAD 
fusions40 (also referred to as neo-TADs3,4); we therefore analyzed 
whether the BA-SVs observed in our cancer cell lines exhibited 
similar neo-TAD formation. We grouped bins on the basis of their 
location compared with the SV breakpoints and the nearest TAD 
boundary. If bins were between the SV breakpoints and the near-
est TAD boundary, we classified these interactions as intra-TAD/
SV and if bins were not constrained by the nearest boundary, we 
classified these interactions as inter-TAD/SV (Fig. 5b). Our analy-
sis revealed that intra-TAD/SV interactions were stronger than the 
inter-TAD/SV interactions, when controlling for genomic distance 
effects, which suggests that the SVs can lead to cross-boundary 
interactions and potentially the formation of new chromatin folding 
domains based on the location of existing nearby TAD boundaries 
(Fig. 5b). For instance, an inversion in OE33 cells that encompassed 
ERBB2 formed a neo-TAD on chromosome 17 (Fig. 5c), a duplica-
tion in HCC1954 cells on chromosome 4 (Fig. 5c) and a duplica-
tion near KRAS in SW480 cells (Extended Data Fig. 9g) resulted in 
a TAD-like configuration between previously disparate two TADs 
(Fig. 5c). These new TAD-like patterns could only be observed in 
cell lines that had the SV, suggesting that these folding patterns were 
the result of a specific alteration (Extended Data Fig. 10a). In all of 
these events, we observed that new interactions spanned the nearest 
boundary and formed ‘triangular shapes’ that were consistent with 
the TAD patterns observed in non-rearranged genomes. Therefore, 
BA-SVs have the potential to form new TAD structures in cancer 
cells that could reconfigure cis-regulatory interactions.
Complex rearrangements markedly change chromatin fold-
ing maps in the cancer genomes. We noticed that complex rear-
rangements in which deletion, inversion or duplication break-ends 
overlapped resulted in marked changes in Hi-C maps. SNU-C1 
cells contain a complex rearrangement (chromothripsis) across the 
entire chromosome 15, which was reported by WGS and spectral 
karyotyping41. This chromosome has 239 rearrangements in the 
SNU-C1 cells and we observed marked changes only in SNU-C1 
Hi-C maps in which the differences in folding patterns overlapped 
with the identified SV break-ends (Fig. 6a, Extended Data Fig. 10b). 
Similarly, we noticed a chromothripsis-like event that covered 
chromosome 21 of HCC1954 cells in WGS data and, similarly, the 
Hi-C map of chromosome 21 in HCC1954 cells showed consider-
able changes (Fig. 6b). In addition to the complex rearrangements 
that covered whole chromosomes, we noticed regional complex 
rearrangements that had abnormal chromatin folding patterns. 
For example, the MYC locus in SW480 cells contains 135 rear-
rangements in a 4-Mb genomic window (Fig. 6c), whereas a larger 
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complex event was observed in HCC1954 cells around the similar 
locus, which also involved two other cancer driver genes, TERT  
and APC, on chromosome 5 (Fig. 6d). We could detect the changes 
in biological Hi-C replicates, suggesting that these BA-SV effects 
are reproducible (Extended Data Fig. 10c). Given that complex 
rearrangements are the most frequent genomic alterations observed 
in the cancer genomes (Fig. 1b), studying the causes and conse-
quences of these events using the chromatin conformation-based 
datasets would be critical for our understanding of the contribution 
of these events to the formation of cancer.
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Discussion
We explored the distributions of somatic SVs in a variety of tumor 
types and their potential roles in the disruption of chromatin folding 
and gene regulation. We found that certain boundaries are affected 
in a cancer-specific manner, which was likely due to the distribution 
of cancer-specific driver genes. Additionally, we observed a differ-
ence between the disruptions between different SV types; deletions 
tended to occur within TADs and LADs, whereas duplications 
tended to span TADs and generally occurred within inter-LAD 
regions. These results suggest that mechanistic differences may 
underlie the generation of different types of SV. For example, genome 
organization may influence partner selection during genomic rear-
rangements, as suggested by the distribution of different SV types 
in the genome to varying degrees. Disruption of folding domains 
could result in aberrant interactions between flanking domains and 
potentially contribute to the re-shaping of gene expression around 
the affected regions. Notably, we did not observe a strong associa-
tion between global changes in gene expression after the disruption 
of each TAD, and only 14% of overall cases resulted in upregulation 
of more than twofold, which is consistent with the findings of recent 
studies42,43. These low expression changes may be reminiscent of 
mutations, in which there is a subset of chromatin-scale events that 
may be more likely to have functional effects (drivers) among a 
backdrop of considerable passenger events. Although we compared 
expression patterns of tumors in this study, cancer genomes may 
have other alterations that could affect the observed gene expression 
patterns, including copy-number alterations, dysregulation of tran-
scription factors, chromatin regulators or cis-regulatory elements44. 
Therefore, the availability of histology-specific matched control 
samples coupled with WGS and chromatin organization datasets 
will augment our understanding of the functions of SV in genome 
folding and transcriptional dysregulation in cancers and contribute 
to our ability to discern signal from noise in appropriate contexts.
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Methods
Hi-C data analysis. Chromatin conformation assay (Hi-C) data for cell lines 
of GM12878, HUVEC, IMR90, HMEC, NHEK and K562 were downloaded 
from GEO (GSE63525). Intra-chromosomal 25-kb-resolution raw observed, 
MAPQGE30-filtered values were normalized by dividing by the multiplication  
of Knight and Ruiz normalization scores for two contacting loci. We calculated  
the TAD signal by moving a window across the Hi-C matrix diagonal, the sum 
of the interaction for a given bin of up to 2-Mb flanking regions and log2 of the 
observed bin to the mean of interaction values within the given 2-Mb window.  
To identify TAD boundaries, we used an approach that is based on insulation  
score calculation18, and called TAD boundaries for each chromosome of each  
cell line with the following parameters: ‘-is 1000000 -ids 200000 -im mean  
-bmoe 1 -nt 0.1 --v’.
To calculate the significance of overlap between different TAD boundary calls, 
we converted the boundary regions into binary bins per genome to compare the 
overlap between previously published IMR90 TAD boundaries4 with our IMR90 
boundary calls. We performed logical AND operation, in which the region is 
counted as overlapping boundaries between two datasets if only two bins for 
the same genomic location of each condition are 1. We used bootstrapping to 
determine the distribution of the random overlap numbers between two calls, and 
calculated P values based on the observed number and distribution of the shuffled 
boundaries. Shuffled boundaries are generated by randomly assigning boundaries 
while keeping the number of boundaries per chromosome constant. Obtained 
shuffled boundaries were also converted to binary string and the same logical  
AND operation was applied. Shuffling was performed 10,000 times for a given 
boundary set. This procedure is applied in the rest of our study to generate  
shuffled boundaries. Next, we computed cumulative distribution of expected 
overlaps, z-scores were calculated based on the observed number and obtained 
distribution from bootstrapping. A two-tailed unpaired Student’s t-test was used  
to calculate P values.
Common TAD boundaries were identified for boundaries of all five cell-types 
(GM12878, HUVEC, IMR90, HMEC and NHEK) that occurred within two Hi-C 
bins or 50 kb in genomic range. The same bootstrapping method (described 
above) was applied to calculate the significance of the overlap between common 
boundaries with TAD boundaries from the cancer cell lines K562 and MCF7.
To cluster individual TADs (defined as genomic regions between two adjacent 
common boundaries) based on epigenetic modifications, we used a comprehensive 
epigenome-profiling dataset from various human cell types. To this end, we 
used an entropy-based approach (epilogos) to calculate the occurrence of each 
chromatin state enrichment for a given genomic region across all cell types 
profiled by Roadmap Epigenome Consortia (http://compbio.mit.edu/epilogos/). 
We calculated the ratio of a TAD genomic space covered by each chromatin state, 
divided by the length of the TAD, and generated a normalized matrix in which 
columns are TADs and rows are each chromatin state, which have been extensively 
studied by the Roadmap Epigenome Consortia21. We applied hierarchical clustering 
to rows to identify similar chromatin states and k-means clustering to columns to 
group TADs that contain similar epigenetic modifications. We performed k-means 
clustering with k = 2–8 clusters and decided on k = 5 clusters as previous chromatin 
studies17,19 have used 5 distinct epigenetically modified chromosomal domains and 
k = 5 corresponded to better visually discernible domains. To determine how our 
TAD clustering correlate with gene expression in cancer-free and cancerous tissues, 
we downloaded normalized gene expression values for 2,663 different cancer-free 
samples from the GTEx Portal36 (v.1.6) and used normalized gene-expression 
values for ICGC cancer samples. We plotted the median expression of the genes 
in GTEx and ICGC samples, located in each domain type. Expression differences 
between heterochromatin and repressed domain expression with active domain 
expression were tested with one-tailed Mann–Whitney U-test. We also calculated 
the total number of genomic regions covered by each domain type. Finally, 
identified open and closed chromatin compartments (at a 100-kb resolution) 
in cancer samples using DNA methylation levels were identified as described 
previously37. We determined the percentage of our domain calls covered with open 
and closed chromatin calls from available cancer types.
We used HiCPlotter45 to plot Hi-C data with different features, TAD 
boundaries or gene-expression fold changes after deletion between repressed and 
active domains.
ENCODE and Roadmap data. ENCODE replication timing data were 
downloaded from the UCSC Genome Browser ENCODE portal for the following 
cell types: BJ, GM06990, GM12801, GM12812, GM12813, GM12878, HeLa-S3, 
HepG2, HUVEC, IMR-90, K-562, MCF-7, NHEK and SK-N-SH. Replication 
timing values for smoothed wavelength transformed data were binned into 25-kb 
windows across the genome to discretize the data. Averages of the values in each 
bin across all cell types were calculated and used as average replication timing 
throughout the study.
We downloaded CTCF binding sites and DNase I hypersensitivity for five cell 
types (GM12878, HUVEC, IMR90, HMEC, NHEK) from the UCSC Genome 
Browser ENCODE portal. In addition, H3K9me3 and input DNA ChIP–seq 
alignment files (.bam) for each cell type were also downloaded. We randomly 
selected the same number of alignment reads for H3K9me3 and input DNA from 
.bam files and calculated log2-transformed enrichment levels of H3K9me3 over 
input DNA.
We downloaded all available CTCF peak-calling results and DNase I 
hypersensitivity regions from the UCSC Genome Browser ENCODE portal from 
80 and 115 different cell lines, respectively (Supplementary Table 11). Occurrences 
of CTCF-binding and DNase I hypersensitivity sites per 25-kb window across the 
genome were calculated for all downloaded cell types and used to calculate TAD 
boundary and shuffled boundary enrichments.
Structural alterations. Somatic and germline variant calls, mutational signatures, 
subclonal reconstructions, transcript abundance, splice calls and other core  
data generated by the ICGC/TCGA PCAWG Consortium are described by  
the lead paper22 of the PCAWG Consortium and available for download at  
https://dcc.icgc.org/releases/PCAWG. Additional information on accessing the 
data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. 
In accordance with the data access policies of the ICGC and TCGA projects, most 
molecular, clinical and specimen data are in an open tier that does not require 
access approval. To access potentially identifying information, such as germline 
alleles and underlying sequencing data, researchers will need to apply to the 
TCGA Data Access Committee (DAC) via dbGaP (https://dbgap.ncbi.nlm.nih.
gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, and to 
the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) for the 
ICGC portion. In addition, to access somatic SNVs derived from TCGA donors, 
researchers will need to obtain dbGaP authorization.
We obtained the consensus SV calls and annotations of each variation 
(deletions, inversions, duplications and complex rearrangements), which can be 
found at Synapse (https://www.synapse.org/) with accession number syn7596712. 
The SV classification algorithm is comprehensively defined in another study23.  
The code for the classification algorithm is available on GitHub (https://github.
com/cancerit/ClusterSV/). In brief, this algorithm clusters individual SV junctions 
into SV events that may involve multiple junctions. The single junction events  
were interpreted, as the ‘basic’ SV types (deletion, tandem duplication, 
translocation and inversions). However, in many cases events involving multiple 
SV junctions were detected. The SV events that involved many SV junctions  
could not be classified into any simple SV types. Therefore, these SV events  
were classified as complex. We specifically focused on the events that occurred 
within a chromosome in this study; we therefore did not use the translocation 
event calls between different chromosomes. To understand the effects of SVs, we 
first grouped the deletions, inversions or duplications on the basis of the length  
of the SVs.
Short-range SVs were identified as events with a length of less than 2 Mb and 
we mainly focused on these events in this study. BA-SVs were identified as SVs that 
spanned the whole length of a TAD boundary, the rest of the SVs were classified as 
‘within TAD’ in Fig. 1b. To determine the distribution of random BA-SV events, we 
used the same bootstrapping method mentioned above, mainly generated random 
boundary events 10,000 times and calculated random BA-SV event distributions. 
The z-scores and P values were calculated on the basis of the observed number and 
distribution obtained from bootstrapping. In this study, we analyzed each event 
separately for deletion, duplication and inversion calls, albeit in a given sample 
these events might occur concurrently.
Long-range SVs were identified as events with a length of more than  
2 Mb and we mentioned the results obtained with long-range SVs in the main  
text, as appropriate.
To understand the germline BA-SV occurrences, we downloaded structural 
alteration calls from three different studies: deletion events (total of 8,941) 
from WGS data of the 1000 Genomes project26; deletions (total of 7,511) and 
duplications (total of 7,501) from WGS data from 236 individuals representing  
125 human populations27; and from a comprehensive review of deletions (total  
of 11,530) and duplications (total of 1,170) events from 23 different studies 
including 2,647 different individuals25. We noticed that the number of BA-SVs 
present in germline deletions and duplications was low and these events  
happened less than expected by chance, which was estimated using a  
bootstrapping method.
We next profiled short-range SVs and BA-SVs for each of the cancer studies in 
our ICGC dataset. To calculate the average number of SVs or BA-SVs per sample 
for each of the cancer studies, we divided the sum of all observed short-range SVs 
or BA-SVs in a given cancer type by the total number of samples in that cancer 
study. Observed SVs and BA-SVs across cancer studies were plotted as stacked bar 
charts representing deletions, inversions and duplications.
To identify the recurrently affected boundaries in each cancer study, we 
generated a matrix in which each column represented a sample in the cancer study 
and rows represented the TAD boundaries. A binary score was assigned to each 
row (a TAD boundary) that indicated whether that boundary was affected by 
BA-SV(s) in a given sample. Boundaries that were affected in more than 10% of 
the samples in a cancer study, are reported as recurrently affected boundaries in 
Supplementary Table 2. The median length of SVs per cancer type was calculated 
for all observed short-range SVs in each cancer type and plotted with the standard 
deviation of lengths. Constitutive insulated neighborhoods were obtained from 
Supplementary Table 8 of a previous study15 and SVs that affected only one anchor 
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(CTCF-binding site) of an insulated neighborhood were considered as loop-
disrupting SVs.
We determined flanking domain annotations of BA-SVs, by identifying the 
type of the nearest domain for the break-ends of each BA-SV. This analysis resulted 
in a half-matrix that contained the observed frequencies of pair-wise flanking 
domain types. We plotted the observed values for BA-SV deletions, inversions, 
duplications or complex rearrangements separately. To understand the genomic 
distribution of domain neighborhoods, we counted the flanking domains of each 
TAD boundary.
To profile SVs between nuclear LADs and inter-LADs, we obtained HMM state 
calls from three different human cell types for constitutive LADs and constitutive 
inter-LADs34 from GSE22428. For a filter, we used LAD calls from an independent 
study3. Genomic coordinates were converted to the hg19 assembly with the 
UCSC liftover tool. To calculate the significance of the observed overlaps between 
different SV types and constitutive LAD and constitutive inter-LADs, we used the 
same bootstrapping method, in which break-ends of each SV type were randomly 
shuffled on the same chromosome 10,000 times and z-scores were calculated 
between observed and expected values.
We identified the nearest genes to the break-ends of BA-SVs as the nearest 
RefSeq genes that did not overlap with the break-ends. The RefSeq gene table 
was downloaded from the UCSC Genome Browser in May 2016. We called 
genes located upstream of the 5′ end of an SV upstream genes and genes located 
downstream of the 3′ end of an SV downstream genes for each BA-SV. Fold 
changes in expression for each of the upstream and downstream genes were 
calculated by dividing observed normalized RPKM values in the particular sample 
with BA-SVs, with average normalized RPKM values in the rest of the same cancer 
study samples. We filtered the genes with low expression values (<0.1 FPKM), as 
fold changes with those genes would be seemingly high for even small fluctuations. 
Copy-number variations could be another confounding factor for observed gene-
expression fold changes. Therefore, we obtained consensus copy-number calls for 
the ICGC cohort based on consensus SV results. We removed cases in which copy 
numbers are more than four for either the upstream or the downstream genes. In 
addition, we removed genes that were distal to the break-ends by more than 1 Mb. 
Expression differences between genes that flanked different BA-SV break-ends 
were tested using one-tailed Mann–Whitney U-tests.
We used pyvcf (https://pyvcf.readthedocs.org) to load .vcf files and pybedtools46 
to perform genomic-interval analyses.
Cancer cell lines. The colon cancer cell lines (SW480, SNU-C1) and breast 
adenocarcinoma cancer cell line (HCC1954) were obtained from the American 
Type Culture Collection and the esophageal adenocarcinoma (OE33) cell line was 
obtained from Sigma-Aldrich. Stocks were stored in liquid nitrogen. These cell 
lines were authenticated by comparing SV results from previous WGS datasets 
from the same cancer lines.
WGS data analysis of cancer cell lines. We obtained the WGS datasets of the 
SW480, SNU-C1 and OE33 cell lines from previous publications41,47,48. To identify 
consensus SVs for SW480 and OE33 cell lines, we ran DELLY49, Lumpy50 and 
BRASS51 algorithms. SV breaks-ends reported by two different callers were 
included in this analysis. For the SNU-C1 cell line, SV calls were obtained from 
Supplementary Table 2 of a previous publication41, genomic coordinates were 
converted to the hg19 assembly using the UCSC liftover tool. HCC1954 whole-
genome data were previously analyzed by the ICGC Structural Variation subgroup 
and we used the consensus structural alterations for this cell line.
Cancer cell line Hi-C assay and analysis. Hi-C was performed using the in situ 
Hi-C protocol as previously described17 using 2–5 million cells per experiment that 
were digested with the MboI restriction enzyme and analyzed in duplicate. Hi-C 
libraries were sequenced on a NextSeq 500 or a HiSeq 4000. Reads were aligned to 
the hg19 reference genome using BWA-MEM52 and PCR duplicates were removed 
using Picard. Hi-C interaction matrices were generated using in house pipelines, 
and matrices were normalized using the iterative correction method53. ATAC-seq 
data for the OE33 cell line were obtained from a previous study54 and H3K27ac 
ChIP–seq datasets for the HCC1954 and SW480 cell lines were obtained from Hon 
et al.55 and Rahnamoun et al.56, respectively.
To investigate the potential function of SVs in TAD fusions, we classified the 
interactions on the basis of the nearest TAD boundary. For each SV, the average 
interaction frequency was calculated within a 2-Mb region of the SV. This average 
frequency ratio was used to ‘scale’ the interactions to account for ploidy. This was 
done by taking the average interaction frequency over that region and dividing 
it by the genome-wide average (controlling for the distance between loci) over a 
window of identical size. Certain WGS-defined SVs do not appear to have a signal 
in the Hi-C data, possibly due to false-positive SV calls, and we excluded regions 
for which the scaling factor was less than 0.1 to remove potential false-positive 
calls. In addition, we truncated the default 2-Mb window if there was another SV 
to avoid biases introduced by complex variants.
Reporting Summary. Further information on research design is available in the 
Life Sciences Reporting Summary linked to this article.
Data availability
Aligned sequencing data, as well as somatic and germline variant calls from 
PCAWG tumors, including SNVs, indels, copy number alterations and SVs, 
are available for download at https://dcc.icgc.org/releases/PCAWG. Additional 
information on accessing the data, including raw read files, can be found at https://
docs.icgc.org/pcawg/data/. In accordance with the data-access policies of the ICGC 
and TCGA projects, most molecular, clinical and specimen data are in an open tier 
that does not require access approval. To access potentially identifying information, 
such as germline alleles and underlying sequencing data, researchers will need to 
apply to the TCGA Data Access Committee (DAC) via dbGaP (https://dbgap.ncbi.
nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, 
and to the ICGC Data Access Compliance Office (DACO; http://icgc.org/daco) 
for the ICGC portion. In addition, to access somatic SNVs derived from TCGA 
donors, researchers will also need to obtain dbGaP authorization.
We obtained the consensus SV calls and annotations of each variation (deletions, 
inversions, duplications and complex rearrangements), which can be found at 
Synapse (https://www.synapse.org/) with accession number syn7596712.
Hi-C data have been deposited at GEO under accession code GSE116694.
Code availability
The core computational pipelines used by the PCAWG Consortium for alignment, 
quality control and variant calling are available to the public at https://dockstore.
org/search?search=pcawg under a GNU General Public License v.3.0, which allows 
for reuse and distribution.
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Extended Data Fig. 1 | See next page for caption.
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Extended Data Fig. 1 | identification of TAD boundaries in different cell types. a, An example region (chromosome2:132-140 Mb) presenting similar 
chromatin folding in 5 different cell types. Heatmaps represent Hi-C data for each cell type. Tiles represent TAD boundary calls for each cell type (red: 
GM12878; green: HUVEC; blue: IMr90; purple: HMEC; orange: NHEK). Triangles depict TAD calls for human ES cells (gray) and IMr90 cell line (gold) 
from a previous study4. b, Venn diagrams show overlap between current IMr90 boundaries (solid) with boundaries (dashed) identified from a previous 
study4 for the IMr90 cell line. c, Aggregate plots show average cell-type specific enrichment levels for Hi-C interaction levels (TAD signal), CTCF binding 
sites, DNAseI hypersensitivity regions and H3K9me3 ChIP-seq levels compared to input DNA around each cell type’s TAD boundaries. d, Overlaps 
between TAD boundaries among 5 different cell lines. Horizontal bars represent total number of TAD boundaries per cell type. Vertical bars represent 
number of intersecting boundaries between cell types. Combination matrix (below), circles indicate that denote cell types are part of the intersection for 
each vertical bars. Common boundaries among all cell types represented with blue vertical bar. e, Histogram represents distribution of TADs length.  
f, Venn diagrams show overlap between common TAD boundaries and leukemia (K562) cell line TAD boundaries. g, Venn diagrams show overlap between 
common TAD boundaries and breast cancer (MCF) cell line TAD boundaries.
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Extended Data Fig. 2 | See next page for caption.
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Extended Data Fig. 2 | Distribution of boundary-affecting structural variations in human cancers. a, Pie charts show the percentages of long-range 
(>2 Mb) and short-range (< = 2 Mb) for deletions (red), inversions (cyan), duplications (green), complex rearrangements (orange) and chromoplexy 
events (purple) in all PCAWG samples. b, Histograms show length distribution of all short-range SVs (solid) or Boundary Affecting SVs (dashed) for 
deletions (red), inversions (cyan), duplications (green) and complex rearrangements (orange) in all PCAWG samples. c, Number of affected boundaries 
(x-axis) per different short-range SV length cut-offs (y-axis). The size of the circles indicates the portion of BA-SVs affecting the specific number of 
boundaries for each length scale. BA-deletion, BA-inversions, BA-duplications and BA-complex rearrangements are represented with red, cyan, green and 
orange colors, respectively. d, Bar charts show TAD-boundary affecting top) deletions (red) and bottom) tandem-duplications (green) in cancer genomes, 
and in genomes of healthy individuals from three different studies.
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Extended Data Fig. 3 | See next page for caption.
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Extended Data Fig. 3 | Histology-specific features of boundary-affecting structural variations. a, Box plots show the length (in Kb) distribution of short-
range SVs (deletions: red, inversions: cyan, duplications: green) for each cancer histology subtypes22. The center line is the median; box limits are the 
upper and lower quantiles; whiskers represent 1.5x the interquartile range. Number of SVs are indicated by each histology name. b, Per sample counts of 
BA-SVs (top) and total SV (bottom) events for breast adenocarcinoma cohort. Deletion, inversions, tandem-duplications and complex rearrangements are 
represented with red, cyan, green and orange colors, respectively. Each bar represents a samples and samples are sorted by the number of BA-SV events.
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Extended Data Fig. 4 | See next page for caption.
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Extended Data Fig. 4 | Further investigation of histology-specific features of boundary-affecting structural variations. a, Distribution of average 
long-range (length of SV>2 Mb) structural variations (deletion (dashed-red), inversion (dashed-cyan), duplication (dashed-green) and complex 
rearrangements (dashed-orange)) per sample for each cancer histology subtypes. b, A recurrently deleted TAD boundary in colorectal adenocarcinoma 
samples near to the RBFOX1 gene. Colored bars on top depict chromosomal locations of the boundaries. Columns of the heatmap are TAD boundaries and 
rows represent each colorectal adenocarcinoma sample. TAD boundaries affected by BA-deletions are colored in red. Schematic below show the deleted 
boundary (red box) near to the RBFOX1 gene. c, Distributions of total SV burden (deletions: red, inversions: cyan, duplications: green, complex: orange) 
across chromosomes. d, Distributions of boundary affecting SVs across chromosomes.
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Extended Data Fig. 5 | Distribution of structural variation burden in different cancer histology subtypes. a, Distribution of boundary-affecting (top) and 
total (bottom) SVs (deletions: red, inversions: cyan, duplications: green, complex: orange) across chromosomes in each cancer histology subtypes22.
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Extended Data Fig. 6 | See next page for caption.
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Extended Data Fig. 6 | examples of genomic alterations that potentially affect CTCF-CTCF chromatin folding loops. a-b, Potentially affected insulated 
neighborhoods a, in esophageal, gastric and colon adenocarcinoma samples near to the CLCN4 gene and b, in liver-HCC and breast cancers near to BCL6 
gene. Black boxes show TAD boundaries, arcs represent CTCF ChIA-PET loops observed in three different cell types (gray). CTCF ChIP-Seq (from NHEK 
cell line) signal is represented by purple histogram. red vertical bars depict deletions in individual samples.
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Extended Data Fig. 7 | See next page for caption.
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Extended Data Fig. 7 | Classification of TADs based on the epigenetic landscape. a, Box plots show length distributions of different TAD annotations. 
Heterochromatin: 61; Low: 705; repressed: 481; Low-Active: 764; Active: 365. In these and all other boxplots in subsequent figures, the center line is the 
median; box limits are the upper and lower quantiles; whiskers represent 1.5x the interquartile range. b, Pie chart represents percent of mappable genome 
covered by each TAD annotation. c, Box plots represent median expression level (rPKM) for a gene residing in a given TAD annotation for GTEX consortia 
dataset. Number of genes in each annotation group: heterochromatin: 624; low: 2874; repressed: 3690; low-active: 4319; active: 4578. d, Box plots 
represent replication timing (repli-Seq) values divided by domain length (in Kb) for each TAD annotations. Heterochromatin: 61; Low: 705; repressed: 
481; Low-Active: 764; Active: 365. e, Bar plots show percent of a TAD annotation covered by open (orange) or closed (black) chromatin domains calls 
from a previous study37 across different TCGA cancer types.
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Extended Data Fig. 8 | See next page for caption.
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Extended Data Fig. 8 | The majority of the domain disruptions do not result in drastic gene expression changes. a, Occurrence of different SV types 
between domain types. Significance of the observed numbers calculated based on the expected distribution which is based on randomly shuffled boundary 
data, cumulative distribution of expected overlaps, z-scores were calculated based on observed number and obtained distribution from this bootstrapping 
exercise A two-tailed unpaired Student’s t-test was used to calculate p-values. Significantly enriched (E) or depleted (D) numbers are denoted next to  
the numbers. b, Box plots show log2 fold-change for the genes nearest to BA-deletions between repressed-repressed (n: 19; blue; left) or active-active  
(n: 36; red; right) domains. In these and all other boxplots in subsequent figures, the center line is the median; box limits are the upper and lower quantiles; 
whiskers represent 1.5x the interquartile range. c, Box plots show log2 fold-change for the genes nearest to BA-duplication (n: 1008) and BA-complex 
(n: 617) break-ends on different domain types. Here ‘less’ or ‘more’ transcriptionally active refers to the ordering of domain annotations in Fig. 4a (that is 
a low domain is considered less compared to a repressed domain). Fold change was calculated based on the gene’s expression in the sample harboring 
the BA-SV compared to the rest of the samples in the same cancer type. d, Observed (arrows) and expected distribution (histograms) of SVs between 
constitutive LADs and interLADs. The expected distribution is based on randomly shuffled LAD and interLADs. e, Box plots show log2 fold-change for the 
genes nearest to deletion (n: 50), duplication (n: 66) and complex (n: 39) SVs between constitutive LAD and interLADs.
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Extended Data Fig. 9 | Cell-type specific alterations of chromatin folding patterns by different structural variation types. a, Pie chart represents the ratio 
of BA-SVs with detectable changes in Hi-C data from HCC1954, OE33, SNU-C1, SW480 cell lines. b, Average contact enrichment between break-ends of 
BA-SVs in cancerous and non-cancerous cell. Interactions between break-ends of BA-SVs longer than 1 Mb in length were included in this analysis. Breast 
epithelial cell line (HMEC) Hi-C data was used to represent non-cancerous cell interaction profile as the majority of BA-SVs in this analysis (56.3%) 
was detected in breast adenocarcinoma cell line (HCC1954). c, Examples of shortest BA-SVs with detectable changes in Hi-C maps and an SV with no 
detectable changes in Hi-C maps. Contact frequencies (log2) of each cell type, plotted with a 20KB (SW480) and 40Kb (HCC1954) window size. Arcs 
below represent SV breakpoint locations with rearrangements coded by color. Green: tandem duplication; red: deletion; cyan and purple: inversion. (Left) 
an 460Kb long duplication in SW480 cells; (middle) an 800 kb long deletion in HCC1954 cells; (right) a duplication overlapping with a translocation in 
HCC1954 cells resulted in no apparent contact map change. d-f) represented regions for the effects of ‘simple’ genomic rearrangements on chromatin 
folding domains: d, A deletion on chromosome 4 in OE33 cells; e, A duplication on chromosome 14 in HCC1954 cells; f, A large inversion and a small 
deletion on chromosome 8 in SNU-C1 cells. g, A duplication (green arc) in SW480 cells results in a TAD-like formation on chromosome 4. Below 
histograms show CTCF and H3K27AC ChIP-Seq data from NHEK and SW480 cell lines, respectively. red dashed line denotes the location of distinct 
genomic regions.
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Extended Data Fig. 10 | Specificity and reproducibility of chromatin organization alterations in cancer cell lines. a, Hi-C data around the neoTAD regions 
demonstrated in Fig. 5c and Supplementary Fig 10g in all cell lines. b, A smaller window of chromosome 15 represented in Fig. 5d which depicts a massive 
chromothripsis event covering all of the chromosome15 in SNU-C1 cell line. c, Biological reproducibility of SV’s effect on chromatin folding patterns 
represented for each Hi-C replicates of cell lines. Contact frequencies (log2) of each cell type, plotted with a 40Kb window size. Arcs below represent SV 
breakpoint locations with rearrangements coded by color. Green: tandem duplication; red: deletion; cyan and purple: inversion.
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Data collection Data and metadata were collected from International Cancer Genome Consortium (ICGC) consortium members using custom software 
packages designed by the ICGC Data Coordinating Centre. The general-purpose core libraries and utilities underlying this software have 
been released under the GPLv3 open source license as the "Overture" package and are available at https://www.overture.bio. Other data 
collection software used in this effort, such as ICGC-specific portal user interfaces, are available upon request to contact@overture.bio. 
Data analysis The workflows executing core WGS alignment, QC and variant-calling software are packaged as executable Dockstore images and 
available at: https://dockstore.org/search?labels.value.keyword=pcawg&searchMode=files. Individual software components are as 
follows: BWA-MEM v0.78.8-r455; DELLY v0.6.6; ACEseq v1.0.189; DKFZ somatic SNV workflow v1.0.132-1; Platypus v0.7.4; ascatNgs 
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VariantBAM v2017Dec12; SNV-Merge v2017May26; SV-MERGE v2017Dec12; DKFZ v2016Dec15; Control-FREEC-11.0;  pyvcf v0.6.7; 
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- Accession codes, unique identifiers, or web links for publicly available datasets 
- A list of figures that have associated raw data 
- A description of any restrictions on data availability
WGS somatic and germline variant calls, mutational signatures, subclonal reconstructions, transcript abundance, splice calls and other core data generated by the 
ICGC/TCGA Pan-cancer Analysis of Whole Genomes Consortium are available for download at https://dcc.icgc.org/releases/PCAWG. Additional information on 
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accessing the data, including raw read files, can be found at https://docs.icgc.org/pcawg/data/. In accordance with the data access policies of the ICGC and TCGA 
projects, most molecular, clinical and specimen data are in an open tier which does not require access approval. To access potentially identification information, 
such as germline alleles and underlying sequencing data, researchers will need to apply to the TCGA Data Access Committee (DAC) via dbGaP (https://
dbgap.ncbi.nlm.nih.gov/aa/wga.cgi?page=login) for access to the TCGA portion of the dataset, and to the ICGC Data Access Compliance Office (DACO; http://
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Sample size We compiled an inventory of matched tumour/normal whole cancer genomes in the ICGC Data Coordinating Centre. Most samples came 
from treatment-naïve, primary cancers, but there were a small number of donors with multiple samples of primary, metastatic and/or 
recurrent tumours. Our inclusion criteria were: (i) matched tumour and normal specimen pair; (ii) a minimal set of clinical fields; and (iii) 
characterisation of tumour and normal whole genomes using Illumina HiSeq paired-end sequencing reads.  
We collected genome data from 2,834 donors, representing all ICGC and TCGA donors that met these criteria at the time of the final data 
freeze in autumn 2014. 
Data exclusions After quality assurance, data from 176 donors were excluded as unusable. Reasons for data exclusions included inadequate coverage, 
extreme bias in coverage across the genome, evidence for contamination in samples and excessive sequencing errors (for example, through 8-
oxoguanine).
Replication In order to evaluate the performance of each of the mutation-calling pipelines and determine an integration strategy, we performed a large-
scale deep sequencing validation experiment. We selected a pilot set of 63 representative tumour/normal pairs, on which we ran the three 
core pipelines, together with a set of 10 additional somatic variant-calling pipelines contributed by members of the SNV Calling Working 
Group. Overall, the sensitivity and precision of the consensus somatic variant calls were 95% (CI90%: 88-98%) and 95% (CI90%: 71-99%) 
respectively for SNVs. For somatic indels, sensitivity and precision were 60% (34-72%) and 91% (73-96%) respectively. Regarding SVs, we 
estimate the sensitivity of the merging algorithm to be 90% for true calls generated by any one caller; precision was estimated as 97.5% - that 
is, 97.5% of SVs in the merged SV call-set have an associated copy number change or balanced partner rearrangement. 
We have performed replication for our Hi-C experiments and the pearson correlation between replicates was 99%.
Randomization We performed randomization to generate synthetic datasets for chromatin domain organization and structural variation distributions.
Blinding No blinding was undertaken, as our Hi-C experiments did not require any blinding.
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Population characteristics Patient-by-patient clinical data are provided in the marker paper for the PCAWG consortium (Extended Data Table 1 of that 
manuscript). Demographically, the cohort included 1,469 males (55%) and 1,189 females (45%), with a mean age of 56 years 
(range, 1-90 years). Using population ancestry-differentiated single nucleotide polymorphisms (SNPs), the ancestry distribution 
was heavily weighted towards donors of European descent (77% of total) followed by East Asians (16%), as expected for large 
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Committee of the ICGC. Each individual ICGC and TCGA project that contributed data to PCAWG had their own local 
arrangements for ethics oversight and regulatory alignment.
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